Universidad de Antioquia, Medellín, Antioquia, Colombia; Hospital Universitario San Vicente Fundación, Medellín, Antioquia, Colombia; FUNDARED-MATERNA, Bogotá, Distrito Capital de Bogotá, Colombia.
Cedars-Sinai Medical Center, Department of Obstetrics and Gynecology, Los Angeles, CA, USA; Oregon Health & Science University, Department of Obstetrics and Gynecology, Portland, OR, USA; FUNDARED-MATERNA, Bogotá, Distrito Capital de Bogotá, Colombia.
Pregnancy Hypertens. 2020 Oct;22:204-209. doi: 10.1016/j.preghy.2020.10.004. Epub 2020 Oct 14.
Dysregulation of CD59 may lead to increased complement-mediated end-organ injury in preeclampsia. We sought to determine if soluble CD59 concentrations are altered in preeclampsia with severe features.
Observational case-control study, which enrolled subjects prospectively from six centers in Colombia from 2015 to 2016. Cases had preeclampsia with severe features and controls were either healthy or had chronic hypertension, gestational hypertension, or preeclampsia without severe features. Trained coordinators collected clinical data, blood and urine. Analyses were by test of medians and Spearman's correlation.
Soluble CD59 concentration in plasma and urine, using enzyme linked immunosorbent assays.
In total, 352 subjects were enrolled (104 cases; 248 controls). Compared to healthy women or those with other hypertensive disorders of pregnancy, women with preeclampsia with severe features had increased concentration of CD59 in plasma (P < 0.001) and decreased CD59 in urine (P = 0.01). In sub-group analyses, plasma CD59 concentrations were increased in preeclampsia with severe features compared to healthy controls (P < 0.001) or controls with either chronic hypertension (P = 0.002) or gestational hypertension (P = 0.02). Increased plasma CD59 concentrations correlated with decreased platelet count and increased lactate dehydrogenase, creatinine, aspartate transaminase, urine protein/creatinine ratio, systolic blood pressure and diastolic blood pressure (P < 0.01, all correlations).
In women with preeclampsia with severe features, soluble CD59 concentrations were increased in plasma and decreased in urine, and plasma levels correlated with increased blood pressure and end-organ injury. Soluble CD59 concentrations may help identify a subset of women with preeclampsia that have altered regulation of terminal complement proteins.
CD59 失调可能导致子痫前期中补体介导的终末器官损伤增加。我们试图确定严重特征子痫前期中可溶性 CD59 浓度是否发生改变。
这是一项观察性病例对照研究,于 2015 年至 2016 年期间在哥伦比亚的六个中心前瞻性招募受试者。病例为具有严重特征的子痫前期,对照组为健康人群或患有慢性高血压、妊娠期高血压或无严重特征的子痫前期。经过培训的协调员收集临床数据、血液和尿液。分析方法采用中位数检验和斯皮尔曼相关性检验。
使用酶联免疫吸附试验检测血浆和尿液中的可溶性 CD59 浓度。
共纳入 352 名受试者(104 例病例;248 例对照)。与健康女性或其他妊娠高血压疾病患者相比,严重特征子痫前期患者的血浆 CD59 浓度升高(P<0.001),尿液 CD59 浓度降低(P=0.01)。亚组分析显示,与健康对照组(P<0.001)或慢性高血压对照组(P=0.002)或妊娠期高血压对照组(P=0.02)相比,严重特征子痫前期患者的血浆 CD59 浓度升高。升高的血浆 CD59 浓度与血小板计数降低、乳酸脱氢酶、肌酐、天门冬氨酸转氨酶、尿蛋白/肌酐比值、收缩压和舒张压升高相关(P<0.01,所有相关性)。
在严重特征子痫前期患者中,血浆可溶性 CD59 浓度升高,尿液中 CD59 浓度降低,且血浆水平与血压升高和终末器官损伤相关。可溶性 CD59 浓度可能有助于识别具有补体终末蛋白调节改变的子痫前期患者亚群。